Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of @ to less than @ mmol per liter received patiromer ( at an initial dose of @ g or @ g twice a day ) for @ weeks ( initial treatment phase ) ; the primary efficacy end point was the mean change in the serum potassium level from baseline to week @ .